Strides Pharma Science has informed that it attached Press Release issued by the Company titled: ‘Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis’
The above information is a part of company’s filings submitted to BSE.